We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 21, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Methods for administering anti-IL-5 antibodies
POLYPEPTIDE LOADED POCA NANOPARTICLES FOR ORAL ADMINISTRATION
COMBINATION TREATMENTS AND USES AND METHODS THEREOF
TLR4 AGONISTS AND COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CANCER
COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES THEREOF